标签归档：paclitaxel

Paclitaxel-d5 (benzoyloxy)(Synonyms: 紫杉醇 d5 (苯甲酸))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Paclitaxel-d5 (benzoyloxy) (Synonyms: 紫杉醇 d5 (苯甲酸))

Paclitaxel-d5 benzoyloxy 是 Paclitaxel 的氘代物。Paclitaxel 是一种天然抗肿瘤药，可稳定微管蛋白 (tubulin) 的聚合。Paclitaxel 可导致有丝分裂停滞和诱导细胞凋亡 (apoptosis)，最终导致细胞死亡。Paclitaxel 还可诱导细胞自噬 (autophagy)。

Paclitaxel-d5 (benzoyloxy)(Synonyms: 紫杉醇 d5 (苯甲酸))

Paclitaxel-d5 (benzoyloxy) Chemical Structure

CAS No. : 1261254-56-1

规格 是否有货
1 mg Check price and availability
5 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Paclitaxel-d5 benzoyloxy is the deuterium labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

858.94

Formula

C47H46D5NO14
CAS 号

1261254-56-1
中文名称

紫杉醇 d5 (苯甲酸)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9.

    [3]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36.

    [4]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52.

    [5]. Pan Z, et al. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3.

    [6]. Cadamuro M, et al. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Jun 21.

    [7]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Jun 16.

    [8]. Yilmaz E, et al. Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy. Neuroscience. 2015 Aug 6;300:210-8.

    [9]. Jing C, et al. E7080 enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

7-O-(Amino-PEG4)-paclitaxel

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

7-O-(Amino-PEG4)-paclitaxel  纯度: ≥99.0%

7-O-(Amino-PEG4)-paclitaxel 是一种 PROTAC linker，属于 PEG 类。可用于合成 PROTAC 分子。

7-O-(Amino-PEG4)-paclitaxel

7-O-(Amino-PEG4)-paclitaxel Chemical Structure

规格 价格 是否有货
25 mg ￥9500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

7-O-(Amino-PEG4)-paclitaxel is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC50 & Target

PEGs

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1101.19

Formula

C58H72N2O19
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Paclitaxel-d5(Synonyms: 紫杉醇 d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Paclitaxel-d5 (Synonyms: 紫杉醇 d5)

Paclitaxel-d5 是氘标记的紫杉醇。Paclitaxel 是一种天然抗肿瘤药，可稳定微管蛋白 (tubulin) 的聚合。

Paclitaxel-d5(Synonyms: 紫杉醇 d5)

Paclitaxel-d5 Chemical Structure

CAS No. : 1129540-33-5

规格 价格 是否有货
1 mg ￥14500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Paclitaxel-d5 is a deuterium-labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization[1].

分子量

858.94

Formula

C47H46D5NO14
CAS 号

1129540-33-5
中文名称

紫杉醇 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9.

    [2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Paclitaxel-d5(Synonyms: 紫杉醇 d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Paclitaxel-d5 (Synonyms: 紫杉醇 d5)

Paclitaxel-d5 是氘标记的紫杉醇。Paclitaxel 是一种天然抗肿瘤药，可稳定微管蛋白 (tubulin) 的聚合。

Paclitaxel-d5(Synonyms: 紫杉醇 d5)

Paclitaxel-d5 Chemical Structure

CAS No. : 1129540-33-5

规格 价格 是否有货
1 mg ￥14500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Paclitaxel-d5 is a deuterium-labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization[1].

分子量

858.94

Formula

C47H46D5NO14
CAS 号

1129540-33-5
中文名称

紫杉醇 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9.

    [2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Paclitaxel-d5(Synonyms: 紫杉醇 d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Paclitaxel-d5 (Synonyms: 紫杉醇 d5)

Paclitaxel-d5 是氘标记的紫杉醇。Paclitaxel 是一种天然抗肿瘤药，可稳定微管蛋白 (tubulin) 的聚合。

Paclitaxel-d5(Synonyms: 紫杉醇 d5)

Paclitaxel-d5 Chemical Structure

CAS No. : 1129540-33-5

规格 价格 是否有货
1 mg ￥14500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Paclitaxel-d5 is a deuterium-labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization[1].

分子量

858.94

Formula

C47H46D5NO14
CAS 号

1129540-33-5
中文名称

紫杉醇 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9.

    [2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DHA-paclitaxel(Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DHA-paclitaxel (Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

DHA-paclitaxel是一种由天然脂肪酸DHA共价连接到紫杉醇的C2′-位置组成的惰性前药。紫杉醇部分与微管蛋白结合，抑制微管的分解，从而抑制细胞分裂。与紫杉醇相比，DHA-paclitaxel更特异性地靶向肿瘤细胞，因为肿瘤细胞吸收大量天然脂肪酸作为生化前体和能量来源。

DHA-paclitaxel(Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

DHA-paclitaxel Chemical Structure

CAS No. : 199796-52-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

DHA-paclitaxel is an inert prodrug composed of the natural fatty acid DHA covalently linked to the C2′-position of paclitaxel. The paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to Paclitaxel, DHA-Paclitaxel targets tumor cells more specifically because tumor cells absorb large amounts of natural fatty acids for use as biochemical precursors and energy sources.

分子量

1164.38

Formula

C69H81NO15
CAS 号

199796-52-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sparreboom A, Wolff AC, Verweij J, et al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res. 2003;9(1):151-159.

    [2]. Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DHA-paclitaxel(Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DHA-paclitaxel (Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

DHA-paclitaxel是一种由天然脂肪酸DHA共价连接到紫杉醇的C2′-位置组成的惰性前药。紫杉醇部分与微管蛋白结合，抑制微管的分解，从而抑制细胞分裂。与紫杉醇相比，DHA-paclitaxel更特异性地靶向肿瘤细胞，因为肿瘤细胞吸收大量天然脂肪酸作为生化前体和能量来源。

DHA-paclitaxel(Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

DHA-paclitaxel Chemical Structure

CAS No. : 199796-52-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

DHA-paclitaxel is an inert prodrug composed of the natural fatty acid DHA covalently linked to the C2′-position of paclitaxel. The paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to Paclitaxel, DHA-Paclitaxel targets tumor cells more specifically because tumor cells absorb large amounts of natural fatty acids for use as biochemical precursors and energy sources.

分子量

1164.38

Formula

C69H81NO15
CAS 号

199796-52-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sparreboom A, Wolff AC, Verweij J, et al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res. 2003;9(1):151-159.

    [2]. Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DHA-paclitaxel(Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DHA-paclitaxel (Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

DHA-paclitaxel是一种由天然脂肪酸DHA共价连接到紫杉醇的C2′-位置组成的惰性前药。紫杉醇部分与微管蛋白结合，抑制微管的分解，从而抑制细胞分裂。与紫杉醇相比，DHA-paclitaxel更特异性地靶向肿瘤细胞，因为肿瘤细胞吸收大量天然脂肪酸作为生化前体和能量来源。

DHA-paclitaxel(Synonyms: Taxoprexin; Docosahexaenoic acid-paclitaxel)

DHA-paclitaxel Chemical Structure

CAS No. : 199796-52-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

DHA-paclitaxel is an inert prodrug composed of the natural fatty acid DHA covalently linked to the C2′-position of paclitaxel. The paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to Paclitaxel, DHA-Paclitaxel targets tumor cells more specifically because tumor cells absorb large amounts of natural fatty acids for use as biochemical precursors and energy sources.

分子量

1164.38

Formula

C69H81NO15
CAS 号

199796-52-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sparreboom A, Wolff AC, Verweij J, et al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res. 2003;9(1):151-159.

    [2]. Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Paclitaxel(Synonyms: 紫杉醇)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Paclitaxel (Synonyms: 紫杉醇) 纯度: 99.96%

Paclitaxel 是一种天然抗肿瘤药，可稳定微管蛋白 (tubulin) 的聚合。Paclitaxel 可导致有丝分裂停滞和诱导细胞凋亡 (apoptosis)，最终导致细胞死亡。Paclitaxel 还可诱导细胞自噬 (autophagy)。

Paclitaxel(Synonyms: 紫杉醇)

Paclitaxel Chemical Structure

CAS No. : 33069-62-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥572 In-stock
10 mg ￥520 In-stock
50 mg ￥900 In-stock
100 mg ￥1500 In-stock
500 mg ￥5000 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Paclitaxel 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Toxins for Antibody-Drug Conjugate Research Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • NMPA-Approved Drug Library
  • Terpenoids Library
  • Cytoskeleton Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].

IC50 & Target[1]

Traditional Cytotoxic Agents

 

体外研究
(In Vitro)

Paclitaxel (20 nM; 48 hours) induces programmed cell death and exists a block at the G2/M phase of the cell cycle[1].
Paclitaxel (20 nM; 48 hours) induces a consistent increase in the level of p53[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: MCF-7, MDA-MB-231 cells
Concentration: 20 nM
Incubation Time: 48 hours
Result: Induced programmed cell death.

Cell Cycle Analysis[1]

Cell Line: MCF-7, MDA-MB-231 cells
Concentration: 20 nM
Incubation Time: 48 hours
Result: >60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament.

Western Blot Analysis[1]

Cell Line: MCF-7 cells (harboring wild-type p53)
Concentration: 20 nM
Incubation Time: 48 hours
Result: Induced a consistent increase in the level of p53.

体内研究
(In Vivo)

Paclitaxel (1-20 mg/kg; i.p.; 1 time/2 days for five cycles) obviously induces liver metastases at the low-Paclitaxel group with little influence on primary tumor growth[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MDA-231 xenograft-bearing mice[3]
Dosage: 1, 20 mg/kg
Administration: Intraperitoneal injection; five cycles (1 time/2 days)
Result: Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group.

Clinical Trial

分子量

853.91

Formula

C47H51NO14
CAS 号

33069-62-4
中文名称

紫杉醇
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (117.11 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1711 mL 5.8554 mL 11.7108 mL
5 mM 0.2342 mL 1.1711 mL 2.3422 mL
10 mM 0.1171 mL 0.5855 mL 1.1711 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.44 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (2.44 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (2.44 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.44 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9.

    [2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36.

    [3]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52.

    [4]. Pan Z, et al. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3.

    [5]. Cadamuro M, et al. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Jun 21.

    [6]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Jun 16.

    [7]. Yilmaz E, et al. Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy. Neuroscience. 2015 Aug 6;300:210-8.

    [8]. Jing C, et al. E7080 enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

10-Deacetyl-7-xylosyl paclitaxel(Synonyms: 10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; 10-Deacetyltaxol 7-Xyloside)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

10-Deacetyl-7-xylosyl paclitaxel (Synonyms: 10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; 10-Deacetyltaxol 7-Xyloside) 纯度: 98.19%

10-Deacetyl-7-xylosyl paclitaxel 是 Paclitaxel (一种 microtubule 稳定剂，增强 tubulin 聚合) 的衍生物，相比 Paclitaxel，具有更好的药学活性。

10-Deacetyl-7-xylosyl paclitaxel(Synonyms: 10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; 10-Deacetyltaxol 7-Xyloside)

10-Deacetyl-7-xylosyl paclitaxel Chemical Structure

CAS No. : 90332-63-1

规格 价格 是否有货 数量
10 mg ￥800 In-stock
50 mg ￥2650 询价
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

10-Deacetyl-7-xylosyl paclitaxel 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Toxins for Antibody-Drug Conjugate Research Library

生物活性

10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features. IC50 value: Target: Microtubule inhibitor 10-Deacetyl-7-xylosyl paclitaxel induced mitotic cell cycle arrest and apoptosis as measured by flow cytometry, DNA laddering, and transmission electron microscopy. Pro-apoptotic Bax and Bad protein expression was up-regulated and anti-apoptotic Bcl-2 and Bcl-XL expression down-regulated, which lead to a disturbance of the mitochondrial membrane permeability and to the activation of caspase-9. In turn, caspase-9 activated downstream caspases-3 and -6, but not caspase-8. Bid was also activated by caspase-3. Reversely, treatment with a caspase-10-specific inhibitor could not protect PC-3 cells from 7-xylosyl-10-deacetyl-paclitaxel-triggered apoptosis. Moreover, 7-xylosyl-10-deacetylpaclitaxel had no effect on the expression of CD95 and NF-kappaB proteins, indicating that apoptosis was induced through the mitochondrial-dependent pathway in PC-3 cells.

IC50 & Target

Traditional Cytotoxic Agents

 

分子量

943.98

Formula

C50H57NO17
CAS 号

90332-63-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 33.33 mg/mL (35.31 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0593 mL 5.2967 mL 10.5934 mL
5 mM 0.2119 mL 1.0593 mL 2.1187 mL
10 mM 0.1059 mL 0.5297 mL 1.0593 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.65 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.65 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.65 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Jiang S, et al. Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol. 2008 Jul;33(1):103-11.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务